Trials / Completed
CompletedNCT04544826
A Study of JNJ-77474462 (Bermekimab) in Healthy Participants of Japanese Descent Following Administration of Single Ascending Subcutaneous Doses
A Phase 1 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of JNJ-77474462 (Bermekimab) in Healthy Participants of Japanese Descent Following Administration of Single Ascending Subcutaneous Doses
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to assess the safety and tolerability of JNJ-77474462 following single subcutaneous (SC) administration to healthy participants of Japanese descent.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-77474462 | JNJ-77474462 will be administered as SC injection. |
| DRUG | Placebo | Matching placebo to JNJ-77474462 will be administered as SC injection. |
Timeline
- Start date
- 2020-10-16
- Primary completion
- 2021-08-05
- Completion
- 2021-08-05
- First posted
- 2020-09-10
- Last updated
- 2021-09-29
Locations
1 site across 1 country: Australia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04544826. Inclusion in this directory is not an endorsement.